Amrutanjan Healt

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE098F01031
  • NSEID: AMRUTANJAN
  • BSEID: 590006
INR
510.95
-6 (-1.16%)
BSENSE

Nov 20

BSE+NSE Vol: 10.08 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Cr
Standalone Quarterly Results
Sep'26
Jun'26
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Sep 2026 is 14.85% vs 7.08% in Sep 2025

stock-summary

Standalone Net Profit

YoY Growth in quarter ended Sep 2026 is 23.78% vs 18.31% in Sep 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Sep 2026 is 42.83% vs 21.54% in Sep 2025

stock-summary

Interest

YoY Growth in quarter ended Sep 2026 is -20.00% vs -16.67% in Sep 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Sep 2026 has improved from Sep 2025

Compare Quarterly Results Of Amrutanjan Healt With
Markets Mojo
Figures in Cr
Standalone Quarterly Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
Net Sales
135.18
78.55
56.63
72.09%
Other Operating Income
0.00
0.00
0.00
Total Operating income
135.18
78.55
56.63
72.09%
Raw Material Cost
46.72
48.87
-2.15
-4.40%
Purchase of Finished goods
17.54
2.54
15.00
590.55%
(Increase) / Decrease In Stocks
-3.53
-0.21
-3.32
-1,580.95%
Employee Cost
18.00
7.28
10.72
147.25%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
0.00
0.00
Selling and Distribution Expenses
14.65
0.00
14.65
Other Expenses
18.19
13.03
5.16
39.60%
Total Expenditure (Excl Depreciation)
111.57
71.51
40.06
56.02%
Operating Profit (PBDIT) excl Other Income
23.61
7.04
16.57
235.37%
Other Income
3.02
2.95
0.07
2.37%
Operating Profit (PBDIT)
26.63
9.99
16.64
166.57%
Interest
0.04
0.62
-0.58
-93.55%
Exceptional Items
0.00
0.00
0.00
Gross Profit (PBDT)
26.59
9.37
17.22
183.78%
Depreciation
3.49
2.32
1.17
50.43%
Profit Before Tax
23.10
7.05
16.05
227.66%
Tax
5.82
1.63
4.19
257.06%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
17.28
5.42
11.86
218.82%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
17.28
5.42
11.86
218.82%
Equity Capital
2.89
6.89
-4.00
-58.06%
Face Value
1.00
10.00
0.00
Reserves
0.00
0.00
0.00
Earnings per share (EPS)
5.98
7.87
-1.89
-24.02%
Diluted Earnings per share
5.98
7.89
-1.91
-24.21%
Operating Profit Margin (Excl OI)
17.47%
8.96%
0.00
8.51%
Gross Profit Margin
19.67%
11.93%
0.00
7.74%
PAT Margin
12.78%
6.90%
0.00
5.88%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Quarterly - Net Sales
Net Sales 135.18 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 31.28% vs -31.25% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 14.85% vs 7.08% in Sep 2025

Quarterly - Standalone Net Profit
Standalone Net Profit 17.28 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 295.42% vs -73.01% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 23.78% vs 18.31% in Sep 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 23.61 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 277.76% vs -75.54% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is 42.83% vs 21.54% in Sep 2025

Quarterly - Interest
Interest 0.04 Cr
in Sep 2026

Figures in Cr
stock-summary

QoQ Growth in quarter ended Sep 2026 is 0.00% vs -20.00% in Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 is -20.00% vs -16.67% in Sep 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 17.47%
in Sep 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Sep 2026 has improved from Jun 2026

stock-summary

YoY Growth in quarter ended Sep 2026 has improved from Sep 2025